Sophia Genetics SA (SOPH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $703.25M
Last updated: Nov 17, 2026 at 4:15 PM ET
Sophia Genetics SA (SOPH) Statistics
Sophia Genetics SA (SOPH) has a market cap of $703.25M and an enterprise value of $660.44M. Its share count is up 26.14% from a year earlier. It kept -89.18% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 6.09% below the market cap, as cash exceeds debt.
| Market Cap | $703.25M |
|---|---|
| Enterprise Value | $660.44M |
| Latest price (Nov 17, 2026) | $7.45 |
Key Dates
| Last Earnings Date | Nov 3, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.0x and 9.3x. Its year-end P/S ranged from 2.7x to 20.0x from 2021 to 2025.
| P/S Ratio | 7.0x |
|---|---|
| Forward P/S | 7.4x |
| P/B Ratio | 9.3x |
| P/TBV Ratio | 19.6x |
Price Statistics
The stock is up 72.85% over 52 weeks and trades 2.23% below its 50-day average.
| Beta (1Y) | 1.52 |
|---|---|
| 52-Week Change | +72.85% |
| 1-Month Change | +14.79% |
| 3-Month Change | -10.02% |
| 6-Month Change | +59.19% |
| 5-Year Change | -46.23% |
| Total Return (1Y) | +72.85% |
| Total Return (3Y CAGR) | +26.50% |
| Total Return (5Y CAGR) | -13.72% |
| Return vs SPY (1Y) | +70.59% |
| Max Drawdown (1Y) | -27.24% |
| Max Drawdown (3Y) | -52.67% |
| Sharpe Ratio (1Y) | 0.98 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $7.62 |
| 200-Day Average | $6.07 |
| 52-Week Range | $3.83 to $8.98 |
| RSI (14 Days) | 49.6 |
| Average Volume (20 Days) | 660.89K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.29x current liabilities, and total debt is 0.74x shareholder equity.
| Current Ratio | 2.29x |
|---|---|
| Quick Ratio | 2.16x |
| Debt / Equity | 0.74x |
| Interest Coverage | -11.30x |
Returns and Efficiency
Return on invested capital is -62.30% over the last 12 months, against a 5-year average of -49.67%.
| Return on Equity (ROE) | -118.56% |
|---|---|
| Return on Assets (ROA) | -43.92% |
| Return on Invested Capital (ROIC) | -62.30% |
| Return on Capital Employed (ROCE) | -57.24% |
| ROE (5Y Average) | -70.99% |
| ROA (5Y Average) | -37.15% |
| ROIC (5Y Average) | -49.67% |
| Asset Turnover | 0.52x |
| Inventory Turnover | 4.29x |
| Receivables Turnover | 5.90x |
| Cash Conversion Cycle | 14 days |
Scores
SOPH has an Altman Z-Score of -1.49, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.49 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $90.97M over the last 12 months is up 24.11% from the 12 months before.
| Revenue | $90.97M |
|---|---|
| Revenue Growth (YoY) | +24.11% |
| Gross Profit | $60.44M |
| Operating Income | -$73.21M |
| Pretax Income | -$80.88M |
| Net Income | -$81.13M |
| EBITDA | -$66.20M |
| EBIT | -$74.30M |
| Reported EPS (TTM) | -$0.86 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 37.04% of the $184.73M in total assets.
| Cash and Equivalents | $93.65M |
|---|---|
| Total Debt | $50.83M |
| Net Cash | $42.82M |
| Net Cash Per Share | $0.50 |
| Working Capital | $70.71M |
| Shareholder Equity | $68.43M |
| Book Value Per Share | $0.80 |
| Tangible Book Value | $32.58M |
| Tangible Book Per Share | $0.38 |
| Total Assets | $184.73M |
| Total Liabilities | $116.30M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.24M of capital spending, operating cash flow left -$48.52M of free cash flow.
| Operating Cash Flow | -$42.28M |
|---|---|
| Capital Expenditures | $6.24M |
| Free Cash Flow | -$48.52M |
| FCF Per Share | -$0.57 |
| Depreciation and Amortization | $10.92M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -80.47%.
| Gross Margin | 66.43% |
|---|---|
| Operating Margin | -80.47% |
| Pretax Margin | -88.91% |
| Net Margin | -89.18% |
| EBITDA Margin | -72.78% |
| EBIT Margin | -81.67% |
| FCF Margin | -53.34% |
| Gross Margin (5Y Average) | 65.23% |
Growth
Revenue grew 17.56% a year over 3 years.
| Revenue Growth (3Y CAGR) | +17.56% |
|---|---|
| Revenue Growth (5Y CAGR) | +22.16% |
| Book Value Per Share Growth (2Y CAGR) | -45.53% |
| Tangible Book Per Share Growth (2Y CAGR) | -70.62% |
Dividends and Yields
SOPH does not pay a dividend. Its free cash flow yield is -7.62%.
| FCF Yield | -7.62% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 11 similar companies, SOPH has the highest P/S.
P/S RatioPeer median 2.5x
ROICPeer median 2.72%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.73%
| P/S Ratio | 7.0x vs 2.5x median |
|---|---|
| ROIC | -62.30% vs 2.72% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +24.11% vs +7.73% median |
Analyst Forecast
Consensus estimates put revenue growth at 23.99% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +23.99% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SOPH
What is SOPH's market cap?
Sophia Genetics SA has a market cap of $703.25M. Its enterprise value, which adds debt and subtracts cash, is $660.44M.
How many shares of SOPH are outstanding?
Sophia Genetics SA has 85.51M shares outstanding. The count is up 26.14% from a year earlier.
Does SOPH pay a dividend?
No. Sophia Genetics SA does not pay a dividend.
How much debt does SOPH have?
Sophia Genetics SA has $50.83M of total debt and $93.65M of cash and equivalents, a net cash position of $42.82M.
SOPH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts